改善蛋白尿可能减轻心房的风险:全国性基于人口的队列研究
Yoonkyung Chang1, Min Kyoung Kang2, Tae-Jin Song2
1Department of Neurology, Mokdong Hospital, Ewha Womans University College of Medicine, Seoul 07985, Republic of Korea.
Journal of clinical medicine
|August 29, 2024
概括
蛋白尿,心房动 (AF) 的一个危险因素,可以是可逆的. 改善蛋白尿状态显著降低AF风险,突出显示它是心血管健康的可修改因素.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 流行病学 流行病学
背景情况:
- 蛋白尿是心房动 (AF) 的已知危险因素.
- 蛋白尿症可以呈现为可逆性或持续性疾病.
- 了解蛋白尿状态变化对AF风险的影响至关重要.
研究的目的:
- 研究蛋白尿状态的变化与发展心房的风险之间的关联.
- 分析来自全国大范围普通人口队列的纵向数据.
主要方法:
- 利用了来自1,708,103名接受定期健康检查的参与者的数据.
- 蛋白尿通过滴针尿液分析评估;使用ICD-10代码识别的心房动.
- 采用多变量分析和对对比对风险评估在中位数14.5年的随访.
主要成果:
- 在随访期间发生了41,190例AF病例.
- 增加的AF风险与初始蛋白尿严重程度相关.
- 蛋白尿改善的组与持续的组相比,显示出明显较低的AF风险 (HR:0.751).
结论:
- 蛋白尿状态的改变会影响心房的风险.
- 从蛋白尿中恢复与AF风险降低有关.
- 管理和改善蛋白尿是减少AF发病率的潜在可修改策略.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Antihypertensive Drugs: Angiotensin II Receptor Blockers
614
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
614
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
510
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
510
Factors Affecting Renal Clearance: Renal Impairment
62
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
62


